A highly specific and sensitive massive parallel sequencer-based test for somatic mutations in non-small cell lung...

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Molecular targeting therapy for non-small cell lung cancer (NSCLC) necessitates comprehensive mutation testing for effective treatment selection.
• Current diagnostic methods often require substantial tissue, limiting genetic analysis in patients with limited samples.

Purpose of the Study:

• To develop and validate a next-generation sequencer (NGS)-based, multi-gene test (MINtS) for investigating driver mutations in NSCLC.
• To assess the feasibility and accuracy of the MINtS test using both cytological specimens and snap-frozen tissue samples.
• To address the urgent need for efficient and cost-effective mutation testing in routine clinical practice.

Main Methods:

• Developed the MINtS, an NGS-based assay targeting EGFR, KRAS, BRAF (DNA), and ERBB2, ALK, ROS1, RET (RNA) fusion genes.
• Validated the assay on 96 cytological samples and 190 snap-frozen tissue samples, including those with as low as 1% cancer cell content.
• Assessed RNA quality from 200 cytological samples to ensure suitability for MINtS analysis.

Main Results:

• The MINtS demonstrated high specificity and sensitivity (≥0.99) across tested genes.
• 99% consistency was observed between MINtS and PNA-LNA PCR clamp tests for EGFR mutations in cytological samples.
• Successful analysis of 99% of tissue samples for all investigated genes (DNA and RNA), with 98% of cytological samples yielding high-quality RNA.

Conclusions:

• The MINtS test system is a feasible and accurate method for analyzing "druggable" genes in NSCLC.
• This assay effectively utilizes both cytological and tissue samples, expanding genetic testing options for patients.
• MINtS addresses a critical need for comprehensive mutation profiling, particularly when only cytological specimens are available.